Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study - Centre de Recherche en Cancérologie et Immunologie Nantes Angers Accéder directement au contenu
Article Dans Une Revue Cancer Medicine Année : 2022

Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study

Julien Rohmer
Marie Parrens
  • Fonction : Auteur
Remy Dulery
Krimo Bouabdallah
  • Fonction : Auteur
Mohamad Mohty

Résumé

Background - Intravascular large B-cell lymphoma (lVLBCL) is a very rare type of large B-cell lymphoma. Methods - We conducted a retrospective study on IVLBCL patients treated from 2000 to 2016 in LYSA cooperative group centers. Results - Sixty-five patients were identified in 23 centers. Median age at diagnosis was 69 years (range 23-92). Thirty-four patients (64%) had an IPI score >3 and 40 patients (67%) had a performance status ≥2. The most frequent extra-nodal locations were bone marrow (n = 34; 52%), central nervous system (n = 25; 39%), and skin (n = 21; 33%). Nodal involvement and endocrine system were observed in 34% (n = 22) and 18% (n = 12) of all cases, respectively. Twenty-six patients (41%) had macrophage activation syndrome. Tumor cells were frequently CD5 positive (52%) with a non-germinal center origin (86%). BCL2 was expressed in 87% of all samples analyzed (n = 20) and 43% of patients had a MYC/BCL2 double expression. Fifty-six patients were treated with a regimen of chemotherapy containing rituximab, among whom 73% reached complete remission. The median progression-free survival (PFS) and median overall survival (OS) were 29.4 months and 63.8 months, respectively. History of autoimmune disorder (Hazard ratio [HR] 3.3 [1.4-7.8]; p < 0.01), nodal involvement (HR 2.6 [1.4-5.1]; p < 0.01), lack of anthracycline (HR 0.1 [0-0.4] for use; p < 0.001), or no intensification at first-line regimen (p = 0.02) were associated with worse PFS. High-dose methotrexate use was not associated with better PFS or OS. Conclusions - Our study highlights the aggressive clinical picture of IVLBCL, in particular the frequency of macrophage activation syndrome, and the need for new therapies despite a response to R-CHOP-like regimen similar to non-intravascular diffuse large B-cell lymphomas.

Domaines

Cancer
Fichier principal
Vignette du fichier
Bonnet - Clinical presentation outcome and prognostic markers in patients with intravascular.pdf (1.08 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03693606 , version 1 (23-01-2023)

Licence

Paternité

Identifiants

Citer

Antoine Bonnet, Céline Bossard, Ludovic Gabellier, Julien Rohmer, Othman Laghmari, et al.. Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study. Cancer Medicine, 2022, 11 (19), pp.3602-3611. ⟨10.1002/cam4.4742⟩. ⟨hal-03693606⟩
76 Consultations
69 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More